Sapient Capital LLC Sells 7,568 Shares of Boston Scientific Corporation $BSX

Key Points

• Sapient Capital LLC reduced its shares in Boston Scientific Corporation by 5.6% in the second quarter, holding 128,038 shares valued at approximately $13.75 million after selling 7,568 shares.
• Multiple institutional investors increased their stakes in Boston Scientific in the first quarter, reflecting a strong overall institutional ownership of 89.07% of the company's stock.
• Boston Scientific recently reported a 22.8% year-over-year revenue growth of $5.06 billion for the quarter, beating analyst estimates of $4.89 billion.

Sapient Capital LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 5.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 128,038 shares of the medical equipment provider's stock after selling 7,568 shares during the quarter. Sapient Capital LLC's holdings in Boston Scientific were worth $13,753,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BSX. GAMMA Investing LLC grew its holdings in shares of Boston Scientific by 11,720.3% during the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after purchasing an additional 2,556,078 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock worth $968,172,000 after buying an additional 1,709,461 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after buying an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Boston Scientific by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after buying an additional 1,664,108 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Boston Scientific by 161.9% during the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after purchasing an additional 1,536,663 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Down 0.4%

Boston Scientific stock traded down $0.39 during mid-day trading on Friday, hitting $97.84. The company had a trading volume of 16,833,754 shares, compared to its average volume of 8,034,038. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock's 50 day moving average price is $104.40 and its two-hundred day moving average price is $102.09. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50. The company has a market capitalization of $144.97 billion, a PE ratio of 58.24, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the company posted $0.62 earnings per share. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $18,397,457 in the last three months. 0.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on BSX shares. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Wells Fargo & Company raised their target price on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Finally, Robert W. Baird raised their target price on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $118.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.